Drug class
CXCR4 Chemokine Receptor Antagonists
CXCR4 chemokine receptor antagonists are a therapeutic class of agents that selectively bind to the C-X-C motif chemokine receptor 4, reversibly blocking its interaction with its endogenous ligand, stromal cell-derived factor-1. Read more about CXCR4 Chemokine Receptor Antagonists
15 drugs in this class 15 manufacturers
Drugs in CXCR4 Chemokine Receptor Antagonists
PLERIXAFOR
APHEXDA (motixafortide acetate)
APHEXDA (motixafortide acetate)
PLERIXAFOR
PLERIXAFOR
CXCR4 chemokine receptor antagonists are a therapeutic class of agents that selectively bind to the C-X-C motif chemokine receptor 4, reversibly blocking its interaction with its endogenous ligand, stromal cell-derived factor-1.
This inhibition disrupts the intracellular signaling pathways responsible for the homing, retention, and chemotaxis of leukocytes and progenitor cells within the bone marrow niche.
Therapeutically, these agents are primarily indicated to mobilize hematopoietic stem cells into the peripheral blood for collection and autologous stem cell transplantation in hematologic malignancies, such as multiple myeloma and non-Hodgkin lymphoma.
Additionally, class members are used to treat WHIM syndrome, a rare primary immunodeficiency characterized by CXCR4 receptor hyperactivity, by releasing retained mature neutrophils and lymphocytes into the circulation.
-
cancer.gov
CXCR4 chemokine receptor antagonists are a therapeutic class of agents that selectively bind to the C-X-C motif chemokine receptor 4, reversibly blocking its interaction with its endogenous ligand, stromal cell-derived factor-1
-
fda.gov
CXCR4 chemokine receptor antagonists are a therapeutic class of agents that selectively bind to the C-X-C motif chemokine receptor 4, reversibly blocking its interaction with its endogenous ligand, stromal cell-derived factor-1 This inhibition disrupts the intracellular signaling pathways responsible for the homing, retention, and chemotaxis of leukocytes and progenitor cells within the bone marrow niche Additionally, class members are used to treat WHIM syndrome, a rare primary immunodeficiency...
-
fda.gov
CXCR4 chemokine receptor antagonists are a therapeutic class of agents that selectively bind to the C-X-C motif chemokine receptor 4, reversibly blocking its interaction with its endogenous ligand, stromal cell-derived factor-1 Therapeutically, these agents are primarily indicated to mobilize hematopoietic stem cells into the peripheral blood for collection and autologous stem cell transplantation in hematologic malignancies, such as multiple myeloma and non-Hodgkin lymphoma
-
drugs.com
Therapeutically, these agents are primarily indicated to mobilize hematopoietic stem cells into the peripheral blood for collection and autologous stem cell transplantation in hematologic malignancies, such as multiple myeloma and non-Hodgkin lymphoma
-
fda.gov
Therapeutically, these agents are primarily indicated to mobilize hematopoietic stem cells into the peripheral blood for collection and autologous stem cell transplantation in hematologic malignancies, such as multiple myeloma and non-Hodgkin lymphoma
-
drugcentral.org
Additionally, class members are used to treat WHIM syndrome, a rare primary immunodeficiency characterized by CXCR4 receptor hyperactivity, by releasing retained mature neutrophils and lymphocytes into the circulation
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.